CA2318493A1 - Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires - Google Patents

Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires Download PDF

Info

Publication number
CA2318493A1
CA2318493A1 CA002318493A CA2318493A CA2318493A1 CA 2318493 A1 CA2318493 A1 CA 2318493A1 CA 002318493 A CA002318493 A CA 002318493A CA 2318493 A CA2318493 A CA 2318493A CA 2318493 A1 CA2318493 A1 CA 2318493A1
Authority
CA
Canada
Prior art keywords
antigen
mice
vaccine
dna
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA002318493A
Other languages
English (en)
Inventor
Krishnendu Roy
Shau-Ku Huang
Hugh Sampson
Kam W. Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318493A1 publication Critical patent/CA2318493A1/fr
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des coacervats nanoparticulaires d'acides nucléiques et de polycations qui sont des vaccins efficaces lorsqu'ils sont administrés par voie orale. Ces coacervats particulaires peuvent induire une immunité contre une grande variété d'agents pathogènes et susciter une réaction protectrice contre les allergènes.
CA002318493A 1998-01-16 1999-01-15 Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires Pending CA2318493A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7167998P 1998-01-16 1998-01-16
US60/071,679 1998-01-16
PCT/US1999/000861 WO1999036090A1 (fr) 1998-01-16 1999-01-15 Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires

Publications (1)

Publication Number Publication Date
CA2318493A1 true CA2318493A1 (fr) 1999-07-22

Family

ID=22102881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318493A Pending CA2318493A1 (fr) 1998-01-16 1999-01-15 Administration par voie orale de vaccins d'acides nucleiques au moyen de complexes particulaires

Country Status (9)

Country Link
US (1) US6475995B1 (fr)
EP (1) EP1045700B1 (fr)
JP (1) JP2002509117A (fr)
AT (1) ATE281844T1 (fr)
AU (1) AU749625B2 (fr)
CA (1) CA2318493A1 (fr)
DE (1) DE69921773D1 (fr)
NZ (1) NZ505877A (fr)
WO (1) WO1999036090A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19940794A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Pharmazeutische Zubereitung
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001091808A2 (fr) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugues de nanoparticules en tant que produits radiopharmaceutiques
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
ES2326209T3 (es) 2000-10-27 2009-10-05 Baxter Healthcare S.A. Produccion de microesferas.
ES2307779T3 (es) * 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.
WO2003028657A2 (fr) * 2001-10-03 2003-04-10 The Johns Hopkins University Compositions pour therapie genique orale et procedes d'utilisation associes
US8178128B2 (en) * 2001-12-05 2012-05-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoparticles containing polymeric nucleic acid homologs
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
CA2484251C (fr) 2002-04-30 2015-06-23 University Of South Florida Matieres et procedes visant a prevenir et a traiter des maladies provoquees par des virus a arn
US20050175625A1 (en) * 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US7595303B1 (en) * 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
WO2005002643A2 (fr) * 2003-06-24 2005-01-13 Johns Hopkins University Methode et produits permettant de distribuer des molecules biologiques a des cellules au moyen de nanostructures multicomposants
US20050084513A1 (en) * 2003-10-21 2005-04-21 Board Of Regents Nanocoating for improving biocompatibility of medical implants
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
JP4674288B2 (ja) * 2004-03-31 2011-04-20 恵雄 岡畑 歯科用材料。
US20050266093A1 (en) * 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1758558B1 (fr) 2004-05-12 2013-10-16 Baxter International Inc. Administration de microspheres d'oligonucleotides antisens pour induire une tolerance de cellules dendritiques pour le traitement du diabete de type 1 insulino-dependant
DE602005009954D1 (de) 2004-05-12 2008-11-06 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
WO2006023207A2 (fr) * 2004-08-19 2006-03-02 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Microparticules coacervees utiles pour l'administration a liberation prolongee d'agents therapeutiques
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
US7901711B1 (en) 2006-04-17 2011-03-08 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US8137697B1 (en) * 2004-10-05 2012-03-20 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
WO2006086428A2 (fr) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Particules d'inactivation de toxines
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
EP2034954B1 (fr) * 2006-03-30 2019-02-20 Engene, Inc. Compositions non virales et procédés de transfection de cellules intestinales in vivo
US8449915B1 (en) 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
MX2009001226A (es) 2006-08-04 2009-03-20 Baxter Int Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
NZ599605A (en) 2007-02-19 2013-11-29 Marinepolymer Tech Inc Hemostatic compositions and therapeutic regimens
KR100813224B1 (ko) * 2007-08-24 2008-03-13 한양대학교 산학협력단 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔
US20090163437A1 (en) * 2007-10-16 2009-06-25 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
FR2924349B1 (fr) * 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
EP2123261A1 (fr) 2008-05-20 2009-11-25 Stallergenes S.A. Formulation à particules mucoadhésives pour induire la tolérance immune spécifique à antigène
US20110305768A1 (en) * 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
ES2567455T3 (es) 2008-10-10 2016-04-22 Dara Biosciences, Inc. Nanoemulsiones que comprenden derivados de espicamicina para su uso en el tratamiento del dolor
WO2010049562A1 (fr) 2008-10-28 2010-05-06 Universidade De Santiago De Compostela Systèmes nanoparticulaires élaborés à base de polymères anioniques
EP2373338B1 (fr) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 en tant que cible immunologique
AU2010256511B2 (en) 2009-06-03 2016-01-14 Tobira Therapeutics, Inc. Nucleic acid modulators of glycoprotein VI
KR20130122632A (ko) 2010-10-14 2013-11-07 레가도 바이오사이언스, 인코포레이티드 Clec-2의 핵산 모듈레이터
WO2013163176A1 (fr) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticules pour le traitement d'allergies
MX2015005636A (es) 2012-10-30 2015-11-16 Univ Monash Moléculas inmunoterapéuticas novedosas y sus usos.
ITTO20121107A1 (it) * 2012-12-19 2014-06-20 Idea Medical Devices S R L Composizione a base di polidesossiribonucleotidi e relativi usi
AU2014248090B2 (en) 2013-04-03 2018-08-02 N-Fold Llc Novel nanoparticle compositions
KR20160075532A (ko) 2013-09-25 2016-06-29 아라백스 피티와이 엘티디 신규한 면역치료제 조성물 및 이의 용도
CN103626860A (zh) * 2013-12-04 2014-03-12 江南大学 一种表达低过敏性花生过敏原的乳酸乳球菌重组菌及其应用
CN111700877A (zh) 2014-09-03 2020-09-25 吉倪塞思公司 治疗性纳米粒子和相关的组合物、方法和系统
JP6084759B1 (ja) * 2015-08-17 2017-02-22 積水メディカル株式会社 免疫学的検出方法及びこれに用いるテストストリップ
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
CA2142007C (fr) * 1992-08-11 2007-10-30 Robert Glen Urban Peptides immunomodulateurs
CA2193954A1 (fr) * 1994-06-27 1996-01-04 Vu L. Truong Systeme de transport de gene cible
US5674495A (en) * 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
JP2000514440A (ja) * 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー 遺伝子輸送システム
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof

Also Published As

Publication number Publication date
WO1999036090A9 (fr) 1999-10-14
US6475995B1 (en) 2002-11-05
ATE281844T1 (de) 2004-11-15
DE69921773D1 (de) 2004-12-16
AU2229299A (en) 1999-08-02
EP1045700A1 (fr) 2000-10-25
EP1045700B1 (fr) 2004-11-10
WO1999036090A1 (fr) 1999-07-22
AU749625B2 (en) 2002-06-27
JP2002509117A (ja) 2002-03-26
NZ505877A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
AU749625B2 (en) Oral delivery of nucleic acid vaccines by particulate complexes
US6355276B1 (en) Adhesive drug delivery composition
Hanes et al. New advances in microsphere-based single-dose vaccines
RU2609661C2 (ru) Антигенные композиции респираторного синцитиального вируса и способы
Gómez et al. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis
WO2007024026A1 (fr) Nanoparticule biodégradable ayant un peptide d’épitope de lymphocyte t reconnaissable immobilisé sur ou encapsulé dans celle-ci
JP2015078204A (ja) 免疫調節剤粒子および処置方法
JP2011105730A (ja) 細胞輸送組成物およびこれらの使用
CA2322472A1 (fr) Systeme d'administration modulant la reponse immunitaire
AU2003267986A1 (en) Vaccines to induce mucosal immunity
Lubitz Bacterial ghosts as carrier and targeting systems
Michalek et al. Antigen delivery systems: new approaches to mucosal immunization
JP6934862B2 (ja) 抗マラリア組成物および方法
AU743226B2 (en) Genetic immunization with co-delivery of nucleic acid and cytokines in a single vehicle
CA2341596A1 (fr) Composition microparticulaire
Keegan et al. Biomimetic design in microparticulate vaccines
Byrd et al. Microencapsulated subunit vaccine approach to enterotoxigenic Escherichia coli and other mucosal pathogens
Yan et al. Dependence of ricin toxoid vaccine efficacy on the structure of poly (lactide-co-glycolide) microparticle carriers
EP1143934B1 (fr) Immunisation genetique avec administration conjointe d'acide nucleique et de cytokines
US20230414526A1 (en) Respiratory syncytial virus antigenic compositions and methods
Prajapati et al. In-Vitro And In-Vivo Assessment of Antigen-Encapsulated Dextran Nanoparticles
US20030161889A1 (en) Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
JP2002504521A (ja) 粘膜の微粒子共役ワクチン
Bejugam Development And Evaluation Of Albumin Based Microparticulate System As A Platform Technology For Oral Delivery Of Proteins, Vaccines, And Drugs.
CN114377017A (zh) 叶酸和叶酸修饰在诱导B细胞免疫耐受和靶向mIgM阳性表达的B细胞淋巴瘤中的用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDC Discontinued application reinstated